Discussion
Disc Medicine’s experimental oral therapy bitopertin significantly reduced levels of protoporphyrin IX (PPIX), a light-sensitive molecule, and significantly increased pain-free time in light in a Phase 3 trial involving people with erythropoietic protoporphyria (EPP). That’s according to top-line data from the global Phase 3 APOLLO trial (NCT06910358),…